BPC-157 is the most researched recovery peptide and the most searched peptide in Australia. Here is what the evidence actually shows, what legal access looks like, and how to get a proper prescription.
Start free assessment →This page is for general information purposes only. BPC-157 is a prescription-only medicine in Australia. Access requires assessment and prescription from an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
BPC-157 is the most searched peptide in Australia. It has the largest preclinical research base of any compound in the tissue repair and recovery space, with over 200 published studies examining its interaction with a range of biological repair mechanisms. This page covers what it is, what the research has found, and what proper access looks like in Australia.
BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide derived from a sequence found in human gastric juice. Despite its gastrointestinal origin, research has examined its effects across a wide range of tissue types including tendon, ligament, muscle, bone, and the gastrointestinal tract itself. The breadth of the research base reflects the apparently non-tissue-specific nature of many of the biological mechanisms it interacts with.
At UHD BioHealth, BPC-157 is available as a pre-mixed injectable vial at 2000mcg per ml in 5ml vials, prepared by our licensed Australian compounding pharmacy. No reconstitution is required. It is also available as part of a combination blend with TB-500 for clients whose protocol includes both compounds.
The research into BPC-157 is extensive by peptide standards. Studies have examined its interaction with growth factor signalling pathways relevant to tissue repair, nitric oxide pathways, the local inflammatory environment around damaged tissue, and various specific repair mechanisms in tendon, ligament, muscle, bone, and gut tissue. The consistent finding across this large body of preclinical research is that BPC-157 appears to interact with multiple repair-relevant pathways simultaneously rather than through a single mechanism.
The honest limitation of the BPC-157 evidence base is that the large majority of this research has been conducted in animal models. The human clinical evidence is more limited than the volume of online discussion might suggest. This does not mean it is ineffective in humans, but it does mean the appropriate basis for any individual's decision about whether to use it is a clinical assessment by a qualified doctor rather than extrapolation from animal research.
BPC-157 in Australia comes pre-mixed: At UHD BioHealth, BPC-157 is dispensed as a pre-mixed pharmaceutical-grade solution by our licensed compounding pharmacy. No bac water, no reconstitution, no measuring. This is both more convenient and more accurate than reconstituting a lyophilised powder, and eliminates one of the main sources of error and contamination risk in self-directed use.
Yes, when accessed through the proper framework. BPC-157 is a Schedule 4 prescription-only medicine. It is legal to use when prescribed by an AHPRA-registered medical practitioner and dispensed by a licensed Australian compounding pharmacy. It cannot legally be purchased without a prescription or sourced from overseas or unregulated domestic suppliers.
Complete your health history and goals online. Takes around five minutes and costs nothing.
An AHPRA-registered prescribing doctor reviews your information and prepares a personalised protocol if appropriate.
Once you choose to proceed, your prescription goes to a licensed Australian compounding pharmacy. Cold-chain delivery to your door.
Free assessment, AHPRA-registered prescribing doctor, licensed Australian compounding pharmacy. No cost until you choose to proceed.